Foldable IOLs: dislocation most common explant cause

Article

Dislocation and decentration are, overall, the most common reasons for foldable intraocular lens (IOL) explantation, and the incidence of these complications is rising.

Dislocation and decentration are, overall, the most common reasons for foldable intraocular lens (IOL) explantation, and the incidence of these complications is rising, said Nick Mamalis, MD of the John Moran Centre, University of Utah, USA. Other major causes for explantation are glare and optical aberrations, incorrect lens power and calcification of hydrophilic (hydrogel) IOLs, according to Dr Mammalis.

These are the latest results of the ASCRS/ESCRS survey on foldable IOLs requiring explantation or secondary intervention. This annual survey is now in its ninth year.

"The most common complications involving foldable IOLs have changed very little over the last three years and may continue to be avoided by excellent surgical technique, quality manufacturing, careful IOL folding and insertion, and accurate IOL measurements," Dr Mamalis noted.

The survey comes from questionnaires filled out by contributing surgeons each time they explant a foldable IOL. It discovered that complications vary according to the type of foldable IOL. Dislocation and decentration was the most common complication associated with one-piece silicone IOLs.

Similarly, dislocation/decentration was the most common cause of explantation for three piece silicone, three-piece acrylic and one-piece acrylic IOLs, followed by glare and other optical aberrations. Calcification or opacification was the most common cause of hydrophilic acrylic IOL explantation.

Over the nine years of the survey, the incidence of dislocation decentration has increased.

Dr Mamalis concluded with a plea to surgeons to complete the questionnaire whenever they explant a foldable IOL. The survey is available on the ASCRS website.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.